Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Mise à jour : Il y a 5 ans
Référence : NCT00448435

Femme et Homme

  • | Pays :
  • Japan
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy and safety of GW815SF HFA MDI 25/50µg 1 inhalation bid in comparison with concomitant treatment with salmeterol xinafoate DPI 25µg 1 inhalation bid plus fluticasone propionate DPI 50µg 1 inhalation bid in paediatric patients with asthma. To evaluate the safety of long-term treatment of GW815SF HFA MDI 25/50µg 1 inhalation bid in paediatric patients with asthma.


Critère d'inclusion

  • Bronchial asthma

Liens